Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Recher

Showing results (461-470 of 488) with videos related to

Pageof 49
Sort By:
Blood Cancer Journal|June 3, 2017
Maintenance therapy with alternating azacitidine and lenalidomide in elderly fit patients with poor prognosis acute myeloid leukemia: a phase II multicentre FILO trialM Hunault-Berger, N Maillard, C Himberlin, et al.
The Journal of Allergy and Clinical Immunology|December 3, 2016
Vedolizumab as a successful treatment of CTLA-4-associated autoimmune enterocolitisAlexander A Navarini, Petr Hruz, Christoph T Berger, et al.
British Journal of Haematology|July 2, 2025
A phase 1, first-in-human, dose-escalation study of JNJ-74856665 (dihydroorotate dehydrogenase inhibitor) alone or in combination in patients with AML or MDSEmma Searle, Thomas Cluzeau, Jenny O'Nions, et al.
Hemasphere|August 5, 2021
Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 TrialHartmut Döhner, Argiris Symeonidis, Dries Deeren, et al.
JAMA Oncology|April 26, 2019
Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung CancerFiamma Berner, David Bomze, Stefan Diem, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 30, 2013
Involvement of Toso in activation of monocytes, macrophages, and granulocytesKarl S Lang, Philipp A Lang, Andreas Meryk, et al.
Nature Immunology|June 1, 2026
Editorial Expression of Concern: DOCK8 functions as an adaptor that links TLR-MyD88 signaling to B cell activationHaifa H Jabara, Douglas R McDonald, Erin Janssen, et al.
Journal of Clinical Immunology|February 16, 2024
Post-transplant Inflammatory Bowel Disease Associated with Donor-Derived TIM-3 DeficiencyAdrian Baldrich, Dominic Althaus, Thomas Menter, et al.
Iscience|April 11, 2022
<i>DUX4</i> is a multifunctional factor priming human embryonic genome activationSanna Vuoristo, Shruti Bhagat, Christel Hydén-Granskog, et al.
Nature Immunology|September 19, 2019
SDHA gain-of-function engages inflammatory mitochondrial retrograde signaling via KEAP1-Nrf2Anne-Valérie Burgener, Glenn R Bantug, Benedikt J Meyer, et al.
Pageof 49

Showing results (461-470 of 488) with videos related to

Sort By:
Pageof 49
Blood Cancer Journal|June 3, 2017
Maintenance therapy with alternating azacitidine and lenalidomide in elderly fit patients with poor prognosis acute myeloid leukemia: a phase II multicentre FILO trialM Hunault-Berger, N Maillard, C Himberlin, et al.
The Journal of Allergy and Clinical Immunology|December 3, 2016
Vedolizumab as a successful treatment of CTLA-4-associated autoimmune enterocolitisAlexander A Navarini, Petr Hruz, Christoph T Berger, et al.
British Journal of Haematology|July 2, 2025
A phase 1, first-in-human, dose-escalation study of JNJ-74856665 (dihydroorotate dehydrogenase inhibitor) alone or in combination in patients with AML or MDSEmma Searle, Thomas Cluzeau, Jenny O'Nions, et al.
Hemasphere|August 5, 2021
Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 TrialHartmut Döhner, Argiris Symeonidis, Dries Deeren, et al.
JAMA Oncology|April 26, 2019
Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung CancerFiamma Berner, David Bomze, Stefan Diem, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 30, 2013
Involvement of Toso in activation of monocytes, macrophages, and granulocytesKarl S Lang, Philipp A Lang, Andreas Meryk, et al.
Nature Immunology|June 1, 2026
Editorial Expression of Concern: DOCK8 functions as an adaptor that links TLR-MyD88 signaling to B cell activationHaifa H Jabara, Douglas R McDonald, Erin Janssen, et al.
Journal of Clinical Immunology|February 16, 2024
Post-transplant Inflammatory Bowel Disease Associated with Donor-Derived TIM-3 DeficiencyAdrian Baldrich, Dominic Althaus, Thomas Menter, et al.
Iscience|April 11, 2022
<i>DUX4</i> is a multifunctional factor priming human embryonic genome activationSanna Vuoristo, Shruti Bhagat, Christel Hydén-Granskog, et al.
Nature Immunology|September 19, 2019
SDHA gain-of-function engages inflammatory mitochondrial retrograde signaling via KEAP1-Nrf2Anne-Valérie Burgener, Glenn R Bantug, Benedikt J Meyer, et al.
Pageof 49